October 22, 2018

Strongbridge Biopharma plc Presents Detailed Initial Results from Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 18th Annual Congress of the European NeuroEndocrine Association

 As Previously Reported, SONICS Met its Primary Endpoint With 30 Percent of the ITT Patient Population Reaching & Maintaining Mean Urinary Free Cortisol (mUFC) Normalization F...
Read more
October 22, 2018

Göran Wessman resigns from the Board – joins the Nomination Committee now appointed in Vicore Pharma Holding

Mölndal, October 22, 2018 - Due to personal reasons, Göran Wessman has chosen to resign from the Board of Directors of Vicore Pharma Holding AB (publ) and will instead join the n...
Read more
October 22, 2018

BONESUPPORT starts selling CERAMENT® BONE VOID FILLER Direct in the US via its own New Distributor Network

25 independent distributors contracted Total of 512 distributor reps now selling CERAMENT BVF New distribution network will positively impact North American reported sa...
Read more
October 18, 2018

GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

• Clinically meaningful improvement of +15 ETDRS letters in visual acuity of treated eyes at Week 72 • Continuous bilateral improvement of both visual acuity and contrast sens...
Read more
October 17, 2018

Nordic Nanovector ASA: Change of Date for Q3 2018 Results Presentation and Webcast

Oslo, Norway, 17 October 2018 Nordic Nanovector ASA (OSE: NANO) announces it will present its results for the third quarter 2018 on Tuesday, 6 November 2018 (previousl...
Read more
October 15, 2018

Nomination Committee appointed in respect of AGM 2019 in Oncopeptides

Stockholm – October 15, 2018 – According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held ...
Read more
October 15, 2018

Targovax Reports Encouraging Disease-free Survival (DFS) Data From Tg01 Trial in Resected Pancreatic Cancer

15 October 2018  at 07:16:00  CET 16.1 months median DFS with TG01 and gemcitabine combination for all 32 patients in the trial 19.5 months DFS in 2nd cohort who received an...
Read more
October 12, 2018

GenSight Biologics to present REVERSE data with GS010 at the 2018 Annual Meeting of the American Academy of Ophthalmology

Paris, France, October 12, 2018, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and develop...
Read more
October 12, 2018

Oncopeptides to present at the Jefferies London Healthcare Conference on November 14th

Stockholm – October 12, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies London Healthcare Conference on November 14th ...
Read more
October 12, 2018

Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)

Oslo, Norway, 12 October 2018 Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators will present data and analyses from its non-clinical a...
Read more